Comparison of Additional Surgical Resection Versus Surveillance Only in Patients with Early Esophageal Cancer After Non-curative Endoscopic Resection: A Meta-analysis
In brief
After noncurative esophageal resection, surgery linked to 40% higher 5-year survival
Across seven studies involving 493 patients, additional surgery was associated with 40% higher 5-year overall survival and 34% higher 5-year recurrence-free survival than surveillance. The advantage was not significant for 3-year outcomes or several time-to-event measures, and the evidence comes from nonrandomized studies; whether surgery benefits all eligible patients remains uncertain.
- Journal
- Annals of surgical oncology (Q1)
- Published
- 16 November 2026
- Study design
- Systematic review of cohort studies
- Evidence level
- Level 2, Moderate (CEBM 2a)
- Authors
- Zhou Y, Qi B, Cao J, Cao X, Zhang S, Xu L, et al.
- PMID
- 43040169
- DOI
- 10.1245/s10434-026-20902-y
Why clinicians should know about it
- Picked for Surgical Oncology (paper of the day, 18 November 2026): Meta-analysis directly compares completion surgery with surveillance
Abstract
BACKGROUND: Esophageal cancer is a highly lethal malignant tumor of the digestive system. Patients with early esophageal cancer often undergo endoscopic resection, but postoperative non-curative resection is frequently undertaken because of the presence of high-risk pathological features. Controversy over subsequent management strategies remains. METHODS: A systematic search of PubMed, Web of Science, Embase, and Cochrane databases through September 29, 2026, yielded seven studies involving 493 patients. A meta-analysis was performed using random-effects or fixed-effects models, and study quality was assessed using the Newcastle-Ottawa Scale and the Risk of Bias in Non-randomized Studies of Interventions-I tool. RESULTS: This meta-analysis included seven studies. Compared with surveillance, additional surgery was associated with significantly improved 5-year survival: 5-year overall survival (risk ratio 1.40; 95% confidence [CI] 1.24-1.58), and 5-year recurrence-free survival (risk ratio 1.34; 95% CI 1.08-1.67), all favoring surgery. The pooled hazard ratio for cancer-specific survival also favored surgery (4.64; 95% CI 1.09-19.76). By contrast, the 3-year endpoints and the time-to-event hazard ratios for overall and recurrence-free survival did not reach statistical significance. CONCLUSION: Additional surgery offers significant long-term survival benefits for eligible patients with early-stage esophageal cancer. Clinical decision-making should be individualized, and future high-quality studies are needed to further validate its efficacy across diverse populations.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.